Open AccessRisk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
Author(s) -
Mingming Zhang,
Linghui Zhou,
Houli Zhao,
Yanlei Zhang,
Guoqing Wei,
Ruoxi Hong,
Wenjun Wu,
Huijun Xu,
Linqin Wang,
Fang Ni,
Jiazhen Cui,
Shuixiu Peng,
Chih-Hua Huang,
Alex H. Chang,
Yongxian Hu,
He Huang
Publication year - 2021
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-21-2031
Subject(s) - medicine , multiple myeloma , proportional hazards model , refractory (planetary science) , gastroenterology , confidence interval , oncology , cytokine release syndrome , progression free survival , surgery , chimeric antigen receptor , cancer , chemotherapy , immunotherapy , physics , astrobiology
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy results in high remission rates in patients with relapsed/refractory (R/R) multiple myeloma. However, the factors associated with prognosis following CAR T-cell therapy are unknown.